Business Wire

European Survey Shows Quality Customer Reference Data Critical to Digital Engagement

Share

According to new research from Veeva Systems (NYSE: VEEV), customer data is critical to digital transformation initiatives for European life sciences companies. Findings from the Veeva 2020 European Customer Data Survey reveal that commercial data leaders recognize the value in harmonizing data for a 360-degree view of customers, with 77% citing it as the main driver for better customer data. This is especially critical as more companies transition to digital engagement as a primary way to connect with healthcare professionals (HCPs).

Nearly all (91%) respondents say customer reference data is a global strategic asset. Given the importance of customer data, more than three-quarters have a data quality initiative underway or planned, signaling an industrywide move to improve their data.

“There is increasing urgency throughout the industry to improve the accuracy of customer reference data to better support digital transformation efforts,” said Rebecca Silver, general manager, Veeva OpenData. “Having a complete, full picture of the customer is key to getting the right insights and accelerating digital engagement.”

Barriers to Data Quality and Integration

The majority of respondents (90%) say that field teams are challenged with aging and incomplete data. In fact, most (89%) say that customer data quality is a significant challenge. Issues with poor data quality are likely driving data enhancement programs, with most respondents (88%) citing data improvement as a top priority for their organization.

Over two-thirds have data that exists in multiple, unintegrated systems. This lack of integration makes it harder to access customer data. More than three-quarters cite difficulty matching all channels of data to get a single view of their customer interactions. Majorities (55%) report dissatisfaction enabling reps to engage new HCPs with real-time access to customer data.

The Need for Better Governance

Respondents show a lack of confidence in their organizations’ ability to manage customer reference data and implement successful data management strategies. More than half (57%) say their organizations lack an efficient data governance model and only 10% of companies surveyed strongly agree they are satisfied with their data governance.

Quality data is key to field performance, which explains why the majority of respondents (77%) are focused on better data access to improve sales force effectiveness. Organizations with strong data governance and initiatives to improve data management are more likely to give their reps easy access to customer profiles and fast data change requests (71% vs. 53%).

In other news today, Veeva also announced the findings of the Veeva 2020 North America Customer Reference Data Survey Report revealing that accurate customer data is essential to digital transformation efforts. Read today’s press release to learn more.

The Veeva 2020 European Customer Data Survey examines the current state of data quality within life sciences companies across Europe. The findings represent the experiences and opinions of more than 90 commercial data owners and represent all of the major European markets, with the majority of respondents from France, Italy, the UK, and Spain. Download the full results at veeva.com/EUDataSurvey.

Additional Information

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

Research Highlights
Veeva 2020 European Customer Reference Data Survey

The Veeva 2020 European Customer Reference Data Survey examines the current state of customer reference data within life sciences across Europe through the opinions and experiences reported by commercial data owners. Findings indicate that the quality and integration of data need to be significantly improved.

Satisfaction with Customer Data

  • Most (89%) say that customer data quality is a significant challenge for the businesses they support, with 41% in strong agreement with this statement.
  • Over two-thirds of respondents (68%) report that their organization has customer data in multiple systems.

Importance of Customer Data and Data Governance

  • The majority of respondents (91%) state that their organization views customer reference data as a global strategic asset.
  • The importance of customer data to support life sciences strategic initiatives is well recognized, with 88% of respondents reporting that customer data is essential to launching new products or sales models.
  • A minority (10%) of respondents strongly agree that they are satisfied with their data governance model.

Industrywide Move to Improve Customer Reference Data

  • Organizations are changing their approach to customer data, with 78% of respondents reporting that they are undertaking or planning a customer data enhancement initiative.
  • Top data enhancement initiatives include improving data access and field force effectiveness (77%), gaining a 360-degree view of customers (77%), and enhancing data quality for accurate reporting /analytics (71%).

® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.

Contact information

Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lineage Logistics Enters the Polish Cold Storage Market With the Acquisition of Pago Sp. z o.o.1.12.2020 20:04:00 EETPress release

Lineage Logistics Holdings, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced it has acquired Pago Sp. z o.o. (“Pago”), a leading warehousing, distribution and transport logistics provider in Poland from its current ownership, including Tönnies International Holding GmbH (“Tönnies”). The strategic acquisition marks the Company’s entrance into the Polish market and adds six exceptional assets to Lineage’s global network of temperature-controlled facilities. Lineage was founded and continues to be managed by Bay Grove Capital, LLC (“Bay Grove”), a principal investment firm dedicated to partnering with strong management teams to build long-term platform investments. Financial terms of the transactions were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005951/en/ The acquisition of Pago Sp. z o.o

Sumitomo SHI FW fluidized bed technology – upscaling thermochemical energy storage to a commercial level1.12.2020 19:47:00 EETPress release

One of the largest obstacles in using renewable energy efficiently is the possibility to store energy on a large scale. SaltX Technology AB has partnered with Sumitomo SHI FW (SFW) to solve this in terms of heat energy. "The storage solution is like a "salt battery". It is based on a basic chemical process with a very common material, calcium oxide produced from limestone, with enhanced properties by our nanocoating process", explains Carl-Johan Linér, CEO of SaltX. Simplified, when calcium oxide reacts with water, it turns into calcium hydroxide and releases heat. Respectively, when calcium hydroxide is dried, it absorbs heat. SFW has designed a fluidized bed pilot reactor, which serves as the point of discharge, where the salt releases the heat. The new 100 kW reactor in SaltX's new testing installation in Sweden, near Stockholm, combines the performance of SaltX's patented nanocoated salt with SFW's fluidized bed technology. "SFW's technology has huge potential to take the salt batt

PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets1.12.2020 19:00:00 EETPress release

PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina ® Focus Panel, AmpliSeq™ for Illumina ® Myeloid Panel and the TruSight™ Hereditary Cancer Panel. Adding these panels expands the existing relationship between Illumina and PierianDx, which currently covers use of the PierianDx platform to support genomic reporting in key global markets for the TruSight Oncology 500 portfolio. Performing a comprehensive NGS test and delivering an accompanying genomic report were once only accomplished via a send-out test to a commercial lab. However, in performing tests as send-outs, healthcare organizations relinquish control over samples, turnaround time, and quality. The PierianDx platform enables healthcare organizations to accelerate their precision medicine programs by empowering them to create accurate, timely, and comprehensive clinical genomic repo

Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 20201.12.2020 18:01:00 EETPress release

Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients. Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity

Andersen Global Adds Collaborating Firm in Azerbaijan1.12.2020 17:30:00 EETPress release

Andersen Global expands into Azerbaijan by way of a Collaboration Agreement with independent Baku-based law firm MGB Law Offices, adding coverage and positioning the organization for further expansion between Europe and Asia. Founded in 1995, MGB Law Offices, which has ten lawyers, has been recognized by IFLR1000, Legal500 and Chambers and Partners as the leading law firm in Azerbaijan. Led by Managing Partner Ismail Askerov, the full-service firm offers solutions in various industries such as oil and gas, aviation, banking and finance, insolvency and restructuring, tax, privatization law and foreign investment. The firm’s client base includes blue-chip multinationals, international financial institutions, insurance companies, airlines, telecom companies and other business entities. “We are proud of our ability to consistently deliver best-in-class services, and our comprehensive solutions position us to be one of the most reputable law firms in the market by allowing us to meet the di

Alira Health Achieves AWS Select Consulting Partner Status1.12.2020 17:00:00 EETPress release

Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announced it has recently earned Amazon Web Services (AWS) Select Consulting Partner status. The firm’s newly formed Advanced Analytics practice will leverage AWS’s cloud computing capabilities to provide greater value to clients, providing fully compliant, made-to-measure digital solutions, powered by AWS, that securely enable the use of data generated by the healthcare community and clients’ own internal data. The solutions are provided to customers in the form of Software-as-a-Service (SaaS), seamlessly integrating into existing workflows and designed to support clients in prioritizing research and development (R&D) investments, identifying novel therapeutic areas suitable for corporate business development, and assessing business opportunities. “Technology has the power to solve complex problems and be a transformative tool across the healthcare and life sciences ecosystem,” said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom